ArticleCase reports in hematology2026
Successful Haploidentical Hematopoietic Stem Cell Transplantation for Chemotherapy-Induced Aplastic Anemia in a Breast Cancer Survivor: A Case Report and Literature Review.
Article in Case reports in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced aplastic anemia (AA) is a rare but potentially life-threatening complication in solid tumor treatment. While allogeneic hematopoietic stem cell transplantation (HSCT) is a recognized treatment for AA, haploidentical HSCT (haplo-HSCT) for chemotherapy-induced AA in solid tumor patient survivors remains largely unexplored. We report a unique case of successful haplo-HSCT in a breast cancer survivor who developed AA following chemotherapy. In addition, we conducted a comprehensive literature review on chemotherapy-induced AA in breast cancer patients and its management, with a focus on HSCT outcomes. This case demonstrates the potential efficacy of haplo-HSCT in treating chemotherapy-induced AA in breast cancer survivors. It highlights an important therapeutic option for this rare but severe complication, particularly when matched donors are unavailable. Our experience contributes valuable insights to the limited literature on managing this challenging clinical scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.